Treatment
-
The Crowded Field of Checkpoint InhibitorsDrug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
Drug Costs and Cancer CareExperts discuss the value of cancer treatments in a climate of rising drug prices.
by Kevin McLaughlin
-
What Is Hyper-Progression?Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
-
March 29: The Week in Cancer NewsJury awards damages to man who says Roundup caused his cancer, the FDA proposes national standards for breast density notifications, and a physician questions whether patients with impaired renal function should avoid contrast-enhanced scans.
by Marci A. Landsmann
-
New Tactics for Bladder CancerAfter decades without treatment advances, options for patients with bladder cancer are now more numerous.
by Kendall K. Morgan
-
First Immunotherapy Approved for Breast CancerMedical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
Holding Off on TreatmentPatients diagnosed with low-risk prostate cancer are increasingly opting against immediate surgery or radiation in favor of regularly monitoring their disease.
by Jon Kelvey
-
From the Editor-in-Chief
Synthetic Lethality and Cancer: Aiming an Arrow at Achilles’ HeelInsights about synthetic lethality have been used to develop cancer treatments.
by William G. Nelson, MD, PhD
-
Recognizing AI’s PotentialPathologists and radiologists are leading the way in the use of artificial intelligence (AI) to find and track cancer. Machine learning could lay the foundation for using AI more broadly to advance cancer diagnosis and choice of treatment.
by Stephen Ornes
